Brand Name | INN Name | NDA applicant | Indication | Approval year |
---|---|---|---|---|
Rozerem | Ramelteon | Takeda Global | Insomnia | 2005 |
Chantix | Varenicline tartrate | Pfizer | Smoking cessation | 2006 |
Azilect | Rasagiline mesylate | Teva | Parkinson’s disease | 2006 |
Invega | Paliperidone | Janssen, L.P. | Schizophrenia | 2006 |
Vyvanse | Lisdexamfetamine dimesylate | New River | Attention-deficit hyperactivity disorder | 2007 |
Neupro | Rotigotine | Schwarz Bioscience | Parkinson’s disease | 2007 |
Pristiq | Desvenlafaxine succinate | Wyeth | Major depressive disorder | 2008 |
Relistor | Methylnaltrexone bromide | Progenics | Opioid-induced constipation | 2008 |
Xenazine | Tetrabenazine | Prestwick | Huntington’s disease | 2008 |
Vimpat | Lacosamide | Schwarz Bioscience | Partial-onset seizure disorder | 2008 |
Banzel | Rufinamide | Eisai Inc. | Seizures associated with Lennox-Gastaut syndrome | 2008 |
Nucynta | Tapentadol Hydrochloride | Ortho-McNeil-Janssen | Acute pain | 2008 |
Lusedra | Fospropofol disodium | Eisai Medical | Anesthesia | 2008 |
Savella | Milnacipran yydrochloride | Cypress Bioscience Inc. | Fibromyalgia | 2009 |
Dysport | AbobotulinumtoxinA | Ipsen Biopharm Limited | Cervical dystonia | 2009 |
Fanapt | Iloperidone | Vanda Pharmaceuticals Inc | Schizophrenia | 2009 |
Saphris | Asenapine maleate | Organon USA Inc. | Bipolar I disorder | 2009 |
Sabril | Vigabatrin | Lundbeck Inc. | Complex partial seizure disorder | 2009 |
Qutenza | Capsaicin | NeurogesX Inc. | Neuropathic pain | 2009 |
Ampyra | Dalfampridine | Acorda Therapeutics Inc. | Multiple sclerosis | 2010 |
Xeomin | IncobotulinumtoxinA | Merz Pharmaceuticals GmbH | Cervical dystonia and blepharospasm | 2010 |
Gilenya | Fingolimod | Novartis Pharmaceuticals Corp. | Multiple sclerosis | 2010 |
Latuda | Lurasidone hydrochloride | Sunovion Pharmaceuticals Inc. | Schizophrenia | 2010 |
Viibryd | Vilazodone hydrochloride | Trovis Pharmaceuticals LLC | Major depressive disorder | 2011 |
Horizant | Gabapentin enacarbil | Glaxo Group Ltd. DBA GlaxoSmithKline | Restless legs syndrome | 2011 |
Potiga | Ezogabine | GlaxoSmithKline | Partial seizure disorder | 2011 |
Onfi | Clobazam | Lundbeck Inc. | Seizures associated with Lennox-Gastaut syndrome | 2011 |
Aubagio | Teriflunomide | Sanofi Aventis US LLC | Multiple sclerosis | 2012 |
Fycompa | Perampanel | Eisai Inc. | Partial seizure disorder | 2012 |
Tecfidera | Dimethyl fumarate | Biogen Idec INC | Multiple sclerosis | 2013 |
Trintellix (formerly Brintellix) | Vortioxetine | Takeda Pharmaceuticals USA Inc. | Major depressive disorder | 2013 |
Aptiom | Eslicarbazepine acetate | Sunovion Pharmaceuticals Inc. | Partial seizure disorder | 2013 |
Hetlioz | Tasimelteon | Vanda Pharmaceuticals Inc. | Non-24Â h sleep-wake disorder | 2014 |
Northera | Droxidopa | Chelsea Therapeutics Inc. | Neurogenic orthostatic hypotension | 2014 |
Belsomra | Suvorexant MK4305 | Merck Sharp & Dohme Corp. | Insomnia | 2014 |
Plegridy | Peginterferon beta-1A | Biogen Idec Inc. | Multiple sclerosis | 2014 |
Movantik | Naloxegol | AstraZeneca Pharmaceuticals LP | Opiod-induced constipation | 2014 |